{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018819","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.601052+00:00","generated_at":"2026-06-23T07:40:28.743676+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Syndax prepays $21.5M loan, terminates Hercules Capital credit agreement","bullets":["Prepaid $21.5M to Hercules Capital to satisfy all principal, interest, and fees under Feb 2020 loan; includes $1.0M end-of-term fee and $0.4M prepayment fee.","Hercules released all security interests on Syndax assets; loan agreement fully terminated as of September 23, 2022.","Prepayment does not alter prior guidance: current cash sufficient to fund operations into second half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018819","json":"https://secwatch.observer/filing/0000950170-22-018819.json","markdown":"https://secwatch.observer/filing/0000950170-22-018819.md","text":"https://secwatch.observer/filing/0000950170-22-018819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022018819/0000950170-22-018819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022018819/sndx-20220919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:40:28.743676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}